{
}
Barclays has upgraded Natera's stock rating to Overweight with a $200 price target, citing the company's impressive 158% return over the past year and its successful expansion into new markets, particularly in NIPT and MRD testing. Natera reported a record Q3 revenue of $439.8 million, a 64% increase from the previous year, and is gaining market share in Organ Health. Despite a setback in a lawsuit against Guardant Health, Natera's management remains confident in sustaining growth through its own capabilities.
Barclays has initiated coverage of Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance coverage. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized cancer treatment through innovative liquid biopsy technology.
Barclays has initiated coverage on Guardant Health with an Overweight rating and a price target of $60, citing strong revenue growth of 29.2% and positive developments in MRD surveillance. The stock has surged 26.5% recently, nearing its 52-week high, and analysts expect continued growth driven by advancements in cancer diagnostics and expanded Medicare coverage for its tests. Guardant Health's market capitalization stands at $5.83 billion, with a focus on personalized oncology solutions.
Barclays analyst Luke Sergott has initiated coverage on Exact Sciences (NASDAQ: EXAS) with an Overweight rating. This move highlights the firm's positive outlook on the company's potential in the market. Further details are available for premium subscribers.
Luke Sergott
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Barclays upgrades Natera stock to Overweight with $200 price target
15:13 23.01.2025
Barclays assigns Overweight rating to Guardant Health with $60 price target
United States Dollar
Guardant Health, Inc.
Boehringer Ingelheim KG
Barclays PLC
USA
Luke Sergott
Show more
15:09 23.01.2025
barclays assigns overweight rating to guardant health with price target of sixty dollars
14:38 23.01.2025
Barclays initiates coverage on Exact Sciences with an overweight rating
13:51 23.01.2025
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Supply Chain Management
AI Innovations
Global Trade Developments
Stock Market Updates
Government Economic Policies
Banking Regulations
Funding Rounds & Investments
Retail and Consumer Goods
Industry Mergers & Acquisitions
Global Financial Events
CEO Changes
Government Policies
Workplace Trends
Economic Sanctions
Decentralized Finance (DeFi) Innovations
Central Bank Actions
Cryptocurrency Trends
Countries:
Companies:
NVIDIA Corporation
Tesla, Inc.
Google Inc.
Apple Inc.
TENCENT
Microsoft Corporation
SpaceXCoin USD
Amazon.com, Inc.
Tesmec S.p.A.
Tally Solutions Ltd.
Vanguard S&P 500 ETF
Liechtensteinische Landesbank Aktiengesellschaft
Banco Santander, S.A.
BNP Paribas SA
UniCredit S.p.A.
CATLOKI USD
Credit Suisse Real Estate Fund Siat
Raiffeisen Bank International AG
VeriSign, Inc.
Berkshire Hathaway Inc.
Currencies:
United States Dollar
Indian Rupee
Swiss Franc
Euro
Chinese Yuan
United Arab Emirates Dirham
British Pound Sterling
Saudi Riyal
Qatari Riyal
Singapore Dollar
Kuwaiti Dinar
Japanese Yen
Offshore Chinese Yuan
Azerbaijani Manat
New Taiwan Dollar
People: